The purpose of this study is to collect long-term follow-up data on delayed adverse
events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize
and understand the long-term safety profile of cilta-cel.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05201781 .
State: All Arizona California Georgia Illinois Michigan Minnesota Missouri New Jersey New York North Carolina Pennsylvania Texas
Locations matching your search criteria
United States Arizona Scottsdale Mayo Clinic in Arizona Status: Active
Name Not Available
California Duarte City of Hope Comprehensive Cancer Center Status: Active
Name Not Available
Palo Alto Stanford Cancer Institute Palo Alto Status: Active
Name Not Available
San Francisco University of California San Francisco Status: Active
Contact: UCSF Clinical Trials
Phone: 877-827-3222
Georgia Atlanta Emory University Hospital/Winship Cancer Institute Status: Active
Name Not Available
Illinois Chicago Northwestern University Status: Active
Name Not Available
University of Chicago Comprehensive Cancer Center Status: Active
Name Not Available
Michigan Detroit Wayne State University/Karmanos Cancer Institute Status: Active
Name Not Available
Minnesota Rochester Mayo Clinic in Rochester Status: Active
Name Not Available
Missouri Saint Louis Siteman Cancer Center at Washington University Status: Active
Name Not Available
New Jersey Hackensack Hackensack University Medical Center Status: Active
Name Not Available
New Brunswick Rutgers Cancer Institute of New Jersey Status: Active
Name Not Available
New York Bronx Montefiore Medical Center-Weiler Hospital Status: Active
Name Not Available
New York Icahn School of Medicine at Mount Sinai Status: Active
Name Not Available
Memorial Sloan Kettering Cancer Center Status: Active
Name Not Available
North Carolina Charlotte Carolinas Medical Center/Levine Cancer Institute Status: Active
Name Not Available
Pennsylvania Philadelphia University of Pennsylvania/Abramson Cancer Center Status: Active
Name Not Available
Pittsburgh University of Pittsburgh Cancer Institute (UPCI) Status: Active
Name Not Available
Texas Houston M D Anderson Cancer Center Status: Active
Name Not Available
Cilta-cel (JNJ-68284528/LCAR-B38M chimeric antigen receptor T-cells [CAR-T]) is an
autologous CAR-T therapy that targets B-cell maturation antigen (BCMA), a molecule
expressed on the surface of mature B lymphocytes and malignant plasma cells. There will
be no treatment administered during the study and the data obtained from this study will
help to assess whether there will be long-term cilta-cel-related toxicities. The study
will consist of 2 phases: within the first 5 years after receiving the last dose of
cilta-cel and Year 6 to 15 years after last dose of cilta-cel. Safety evaluations will
include a review of adverse events, laboratory test results, and physical examination
findings (including neurological examination). The duration of the study is up to 15
years after last dose of cilta-cel and participants will be followed at least once per
year.
Trial Phase Phase IV
Trial Type Not provided by clinicaltrials.gov
Lead Organization Janssen Research & Development, LLC
